Sign in

Private company

Baudax Bio, Inc.

American pharmaceutical preparations company, incorporated in Pennsylvania1

In its 2023 annual report the company says: “We are a pharmaceutical company primarily focused on innovative products for hospital and related settings.”44 It is headquartered in Malvern, Pennsylvania.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersMalvern, Pennsylvania1
  • Incorporated inPA2
  • Business address490 Lapp Road, Malvern, Pa 193552
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-4477.0%Operating margin3
-4633.2%Net margin3
17.5%Revenue growth, 20223
-$27.8MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue20¢$7.0M
  • Research and development11¢$3.9M
  • Selling, general and admin69¢$24.1M

Out of $1.3M in revenue.3 The company lost money this year.

Financial statements

Revenue43$1.3M in 2022+157% since 2020
0$500.0K$1.0M$1.5M2020: $493.0K$493.0K20202021: $1.1M$1.1M2021+119%2022: $1.3M$1.3M2022+18%
Operating income5643-$56.8M in 2022−23% since 2018
-$80.0M-$60.0M-$40.0M-$20.0M02018: -$73.5M-$73.5M20182019: -$32.5M-$32.5M2019−56%2020: -$74.8M-$74.8M2020+130%2021: -$19.0M-$19.0M2021−75%2022: -$56.8M-$56.8M2022+199%
Net income5643-$58.8M in 2022−20% since 2018
-$80.0M-$60.0M-$40.0M-$20.0M02018: -$73.7M-$73.7M20182019: -$32.6M-$32.6M2019−56%2020: -$76.1M-$76.1M2020+134%2021: -$19.8M-$19.8M2021−74%2022: -$58.8M-$58.8M2022+197%
Fiscal year201720182019202020212022
Revenue$493.0K4$1.1M3$1.3M3
Cost of revenue$1.7M4$2.4M3$7.0M3
Research and development$35.6M5$20.1M6$9.1M4$3.1M3$3.9M3
Selling, general and admin$27.0M6$43.3M4$45.3M3$24.1M3
Operating expenses$20.1M3$58.1M3
Operating income-$73.5M5-$32.5M6-$74.8M4-$19.0M3-$56.8M3
Interest$1.4M4$2.3M4
Income before tax-$19.8M3-$58.8M3
Income tax$05$06$04$03$03
Net income-$73.7M5-$32.6M6-$76.1M4-$19.8M3-$58.8M3
Earnings per share-$361.163-$177.303
Earnings per share (diluted)-$361.163-$177.303
Shares (weighted, basic)54.7K shares3331.6K shares3
Shares (weighted, diluted)54.7K shares3331.6K shares3

Compare Baudax Bio, Inc. with another company

Corporate structure

Baudax Bio, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Baudax Bio, Inc.

  • Baudax Bio, Inc. Malvern, Pennsylvania

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Baudax Bio, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.1M3 Dec 31, 2022$6.5M3 Dec 31, 2021−67.4%
Accumulated depreciation$1.4M3 Dec 31, 2022$1.5M3 Dec 31, 2021−4.1%
Property and equipment, net$704.0K3 Dec 31, 2022$5.0M3 Dec 31, 2021−86.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$5.3M3 Dec 31, 2022$15.9M3 Dec 31, 2021−66.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.1M3 Dec 31, 2022$2.1M3 Dec 31, 20210%
Intangible assets, net (excluding goodwill)$03 Dec 31, 2022$21.7M3 Dec 31, 2021−100.0%
Finite-lived intangibles, net$21.7M4 Dec 31, 2021$24.3M6 Dec 31, 2020−10.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$03 Dec 31, 2022$5.0M3 Dec 31, 2021−100.0%
Raw materials$26.0K3 Dec 31, 2022$53.0K3 Dec 31, 2021−50.9%
Finished goods$1.6M3 Dec 31, 2022$645.0K3 Dec 31, 2021+145.0%

Leadership

Who has led Baudax Bio, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Geraldine Henwood2019–2022

President

  1. Geraldine Henwood2019–2022

Chief financial officer

  1. Ryan David Lake2019–2021
  2. Richard S. Casten2021
  3. Natalie McAndrew2023
20202025
Board members and other officers (9)

Former names

  • Recro Enterprises, Inc.Jun 24, 2019 to Jun 24, 20192

Timeline

  1. Feb 28, 20248-K Bankruptcy or receivership20
  2. Dec 13, 20238-K Other events21
  3. Nov 15, 20238-K Listing notice or transfer22
  4. Oct 25, 20238-K Change of auditor23
  5. Oct 13, 20238-K Shareholder vote24
  6. Oct 6, 20238-K Executive or director change; Other events25
  7. Sep 29, 20238-K Other events26
  8. Sep 7, 20238-K Financial statements and exhibits27
  9. Sep 5, 20238-K Entered a material agreement28
  10. Aug 25, 20238-K Entered a material agreement; Unregistered sale of shares29
  11. Aug 24, 20238-K Change to shareholders' rights; Bylaws or fiscal year changed30
  12. Aug 21, 20238-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights31
  13. Nov 12, 2019New chief executive Geraldine Henwood becomes CEO9

Calendar

When it reported results

  1. Aug 16, 2023Reported quarterly or annual results32
  2. May 12, 2023Reported quarterly or annual results33
  3. Feb 23, 2023Reported quarterly or annual results34
  4. Nov 8, 2022Reported quarterly or annual results35
  5. Aug 11, 2022Reported quarterly or annual results36
  6. May 5, 2022Reported quarterly or annual results37
  7. Mar 16, 2022Reported quarterly or annual results38
  8. Mar 1, 2022Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

181 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 67 major events, 13 insider forms, 9 large holders, 83 other. The latest 20:

  1. Feb 28, 20248-K EDGAR
  2. Feb 14, 2024SC 13G/A EDGAR
  3. Feb 6, 2024SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G EDGAR
  4. Dec 13, 20238-K EDGAR
  5. Nov 22, 2023424B3 EDGAR
  6. Nov 20, 202310-Q EDGAR
  7. Nov 15, 2023NT 10-Q EDGAR
  8. Nov 15, 20238-K EDGAR
  9. Oct 25, 20238-K EDGAR
  10. Oct 13, 20238-K EDGAR
  11. Oct 11, 20233 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  12. Oct 10, 2023DEFA14A EDGAR
  13. Oct 6, 20238-K EDGAR
  14. Sep 29, 20238-K EDGAR
  15. Sep 25, 2023EFFECT EDGAR
  16. Sep 25, 2023EFFECT EDGAR
  17. Sep 21, 2023CORRESP EDGAR
  18. Sep 21, 2023S-1/A EDGAR
  19. Sep 21, 2023CORRESP EDGAR
  20. Sep 21, 2023S-3/A EDGAR

The 181 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 15, 2022HENWOOD GERALDINEPresident and CEOBuy1,200$2.55$3.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.5M 2020–2020
Money received by yearMoney received by year, 2020–2020: $1.5M in all. PPP loans $1.5M.$0$500K$1M$1.5M$2M2020 · PPP loans: $1.5M2020
Figures by year
YearPPP loansTotal
2020$1.5M$1.5M

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA43. Matched to this company by name and state.

  1. May 1, 2020$1.5M PPP loan (first draw) from PNC Bank, National Association43To BAUDAX BIO INC, Malvern PA; $1.6M forgiven May 21, 2021

SEC filer profile

How Baudax Bio, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBaudax Bio, Inc.1
  • CIK0001780097
  • Employer ID (EIN)47-46395001
  • Filer status<br>emerging growth company1
  • Incorporated inPennsylvania1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address490 Lapp Road, Malvern, PA 193551
  • Phone484-395-24701
  • Shares outstanding43,593,082 as of Nov 10, 20238
  • Public float$6.8M as of Jun 30, 20223
  • On EDGAR sinceJun 24, 20191
  • Filings352 in all: 8-K (110), 4 (48), DEFA14A (22), 424B3 (15), CORRESP (15), 10-Q (13), 3 (13), 424B5 (13)1
    All 34 form types

    SC 13G (13), SC 13G/A (11), UPLOAD (11), DEF 14A (8), EFFECT (8), S-1/A (6), S-8 (6), PRE 14A (5), 10-K (4), 8-K/A (4), S-1 (4), S-3 (4), 10-12B/A (2), 8-A12G (2), NT 10-Q (2), S-3/A (2), SEC STAFF LETTER (2), 10-12B (1), 25-NSE (1), 424B4 (1), ARS (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), PRER14A (1)

  • Latest filingsAnnual report (10-K) Feb 23, 2023
    Quarterly report (10-Q) Nov 20, 2023
    Proxy statement (DEF 14A) Sep 7, 2023
    Latest 8-K (8-K) Feb 28, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44